Saxagliptin is a highly effective dipeptidase -4 inhibitor. By selectively inhibiting dpp-4, endogenous levels of glucagon-like peptide-1 and glucose-dependent insulin-releasing peptides can be increased to regulate blood glucose.

Market Analysis and Insights: Global Saxagliptin API Market
The global Saxagliptin API market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Saxagliptin API Scope and Market Size
The global Saxagliptin API market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Saxagliptin API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Purity≥98%
Purity≥99%

Segment by Application
Saxagliptin Tablets
Other

The Saxagliptin API market is analysed and market size information is provided by regions (countries). Segment by Application, the Saxagliptin API market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
AstraZeneca
Tapi Teva
API Polpharma
Metrochem API
Tianjin Scipharmacn
Taizhou Canova Bio-technology
Minxiang Pharma
Huaman Xincaiiao Keji
Jinan Lead Pharm-Chemical
Hebei Kangtai Pharma